Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung Adenocarcinoma

This publication has 31 references indexed in Scilit:

• Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers
  Lung Cancer, 2007
• Mutational Analysis of EGFR and Related Signaling Pathway Genes in Lung Adenocarcinomas Identifies a Novel Somatic Kinase Domain Mutation in FGFR4
  PLOS ONE, 2007
• A Gene Expression Signature Predicts Survival of Patients with Stage I Non-Small Cell Lung Cancer
  PLoS Medicine, 2006
• Prognosis of patients with resected non-small cell lung cancer: Impact of clinical and pathologic variables
  Lung Cancer, 2006
• Smoking Status as a Prognostic Factor in Patients with Stage I Pulmonary Adenocarcinoma
  The Annals of Thoracic Surgery, 2006
• Prognostic factors in non-small cell lung cancer surgery
  European Journal of Surgical Oncology, 2006
• KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
  PLoS Medicine, 2005
• EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
  Proceedings of the National Academy of Sciences, 2004
• Mutation-Selective Tumor Remission with Ras-Targeted, Whole Yeast-Based Immunotherapy
  Cancer Research, 2004
• Prognostic factors in non‐small cell lung cancer
  Seminars in Surgical Oncology, 2003